Actualizacion en el tratamiento de la colitis ulcerosa

Mayer, 2010, A randomized placebo-controlled trial of MDX-1100, an anti-IP-10 antibody, for moderately-to-severely active ulcerative colitis, Gastroenterology, 139, e17, 10.1053/j.gastro.2010.05.065 Dufour, 2002, IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking, J Immunol, 168, 3195, 10.4049/jimmunol.168.7.3195 Leiper, 2010, Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis, Gastroenterology, 138, S86 Lee, 2010, The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials, Rheumatol Int Fang, 2010, A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma, Ann Hematol, 10.1007/s00277-010-0990-5 Goetz, 2007, Exacerbation of ulcerative colitis after rituximab salvage therapy, Inflamm Bowel Dis, 13, 1365, 10.1002/ibd.20215 Vermeire, 2010, A phase 2a randomized placebo-controlled double-blind multi-center dose escalation study to evaluate the safety, tolerability, pharmacodynamics and efficacy of AG011 in patients with moderately active ulcerative colitis, Gastroenterology, 138, S9 Mazmanian, 2008, A microbial symbiosis factor prevents intestinal inflammatory disease, Nature, 453, 620, 10.1038/nature07008 Sandborn, 2010, Double blind placebo controlled phase IIB trial of HMPL-004 (Andrographis paniculata extract) in active mild to moderate ulcerative colitis (UC), Gastroenterology, 138, S115 Bernstein, 2010, A population based assessment of 5-ASA as chemoprophylaxis in IBD for colorectal cancer, Gastroenterology, 138, S46 Carrat, 2010, Aminosalicylates, thiopurines and the risk of colorectal cancer in inflammatory bowel diseases: a case-control study nested in the CESAME cohort, Gastroenterology, 138, S47 Kane, 2010, Association between compliance and clinical recurrence in patients with quiescent ulcerative colitis receiving MMX® mesalamine 2.4 g/day as maintenance therapy: results of the phase IV simple trial, Gastroenterology, 138, S106 Lichtenstein, 2010, Once-daily mesalamine granules (1.5 g) for maintenance of remission from ulcerative colitis: a subgroup analysis, Gastroenterology, 138, S165 Ito, 2010, A direct comparative study of two different mesalamine formulations revealed appropriate use of mesalamine for patients with active ulcerative colitis depending on the characteristics of disease, Gastroenterology, 138, S166 Stein, 2010, Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide and mesalazine enemes in active left-sided ulcerative colitis, Gastroenterology, 138, S518 Ford, 2010, Efficacy of anti-TNF therapy in ulcerative colitis (UC): a meta-analysis of randomized controlled trials looking at inducing remission in active disease and preventing relapse rates in quiescent disease, Gastroenterology, 138, S520 Waters, 2010, Persistence with infliximab maintenance therapy decreases hospitalizations in patients with ulcerative colitis, Gastroenterology, 138, S317 Chaparro, 2010, Efficacy and safety of infliximab rescue therapy after cyclosporine failure in patients with steroid-refractory ulcerative colitis: a multicenter study, Gastroenterology, 138, S688 Fukunaga, 2010, Prospective randomized double blind sham controlled study to assess the clinical efficacy of monthly selective granulocyte/monocyte adsorption as maintenance therapy in steroid refractory ulcerative colitis patients, Gastroenterology, 138, S521 Cabriada, 2010, Leukocyte-apheresis for steroid-refractory ulcerative colitis. Results of a Nationwide Spanish Registry, Gastroenterology, 138, S701 Cabriada, 2010, Leukocyte-apheresis for steroid-dependent ulcerative colitis. Results of a Nationwide Spanish Registry, Gastroenterology, 138, S701 Nunes, 2010, Usefulness of oral beclometasone dipropionate to induce remission in active ulcerative colitis patients: results from the Reclicu study, Gastroenterology, 138, S694 Reinisch, 2010, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis, Gastroenterology, 138, S114 Taxonera, 2010, Adalimumab for ulcerative colitis patients previously treated with infliximab: outcomes at short and long term and predictors of response, Gastroenterology, 138, S61 García-Bosch, 2010, Efficacy of adalimumab in the treatment of ulcerative colitis, Gastroenterology, 138, S696